Steven R. Hall
Halifax, NS B3H4R2, Canada
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Correction: Pilot study of jadomycin B pharmacokinetics and anti-tumoral effects in zebrafish larvae and mouse breast cancer xenograft models.
Journal: Canadian journal of physiology and pharmacology
Published: February 27, 2023
Pilot study of jadomycin B pharmacokinetics and anti-tumoral effects in zebrafish larvae and mouse breast cancer xenograft models.
Journal: Canadian journal of physiology and pharmacology
Published: August 19, 2022
Decitabine Response in Breast Cancer Requires Efficient Drug Processing and Is Not Limited by Multidrug Resistance.
Journal: Molecular cancer therapeutics
Published: July 30, 2019
Isolation of a jadomycin incorporating L-ornithine, analysis of antimicrobial activity and jadomycin reactive oxygen species (ROS) generation in MDA-MB-231 breast cancer cells.
Journal: The Journal of antibiotics
Published: February 02, 2018
Jadomycins Inhibit Type II Topoisomerases and Promote DNA Damage and Apoptosis in Multidrug-Resistant Triple-Negative Breast Cancer Cells.
Journal: The Journal of pharmacology and experimental therapeutics
Published: March 01, 2017
Jadomycin breast cancer cytotoxicity is mediated by a copper-dependent, reactive oxygen species-inducing mechanism.
Journal: Pharmacology research & perspectives
Published: September 26, 2014
Jadomycins are cytotoxic to ABCB1-, ABCC1-, and ABCG2-overexpressing MCF7 breast cancer cells.
Journal: Anti-cancer drugs
Published: November 16, 2013
Showing 1-8 of 8
Last Updated: 09/26/2026